Axsome Therapeutics, Inc. (AXSM) Stock Analysis

Axsome Therapeutics Inc (AXSM) (Q3 2026) Earnings Call Highlights: Revenue Tops $1 Billion Run ...

Tue, November 3, 2026 at 1:02 AM UTC 4 min read

Axsome Therapeutics Inc (AXSM) reported total revenue of $259.7 million in Q3 2026, marking a 52% increase year-over-year and surpassing a $1 billion annual run rate. AUVELITY net product sales reached $207.6 million, driven by strong demand in major depressive disorder and Alzheimer's disease agitation, while the net loss narrowed significantly to $12.9 million. The company continues to expand its prescription base, particularly in the 65+ age segment, which saw a 211% increase in new-to-brand prescriptions year-over-year.

Read full article →

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Wed, October 28, 2026 at 1:44 PM UTC 4 min read

Axsome Therapeutics (AXSM) has been compared to Moderna in terms of revenue growth and stock volatility. While Moderna has experienced significant fluctuations, Axsome has demonstrated consistent revenue growth, which may appeal to investors seeking stability. This comparison highlights the potential for Axsome to attract investors looking for less risky opportunities in the biotech sector, especially as it continues to advance its pipeline of therapies.

Read full article →